Pharmaceutical Research and Manufacturers of America (PhRMA) has released a report highlighting Texas as a leader in clinical trials conducted by biopharmaceutical companies in collaboration with the state's clinical research centers, university medical schools and hospitals over the last 13 years. This study comes the same week as the announcement of a major partnership between the Texas A&M University system and GlaxoSmithKline to create a state-of-the-art influenza vaccine manufacturing facility at the Texas A&M Center for Innovation in Advanced Development and Manufacturing.
"Texas companies and universities continue to be on the forefront of biotechnology innovation, providing groundbreaking research and therapies to improve the quality of life for individuals across our state and nation and around the world," Gov. Perry said. "I'm proud that Texas has received this recognition, and am committed to ensuring we continue to foster an economic climate that encourages innovation, collaboration and job creation in biotechnology."
According to the National Institutes of Health, Texas ranked second nationally in 2012 for the number of clinical trials conducted in the state, with more than 14,000 studies underway. More than half of clinical trials conducted in Texas targeted the nation's six most debilitating chronic diseases: asthma, heart disease, stroke, cancer, diabetes and mental illness.